Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models — V. Del Gobbo (1991) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models
Shared by
De Clercq Erik
KU Leuven
Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models
Article
1991
en
Authors
+6 more
VG
V. Del Gobbo
AF
Andrea Foli
JB
Jan Balzarini
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1990
Anti‐retrovirus activity of 9‐(2‐phosphonylmethoxyethyl)adenine (pmea) <i>in vivo</i> increases when it is less frequently administered
Jan Balzarini
,
Lieve Naesens
,
De Clercq Erik
Article
1997
Potent antitumor activity of the differentiation-inducing agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in choriocarcinoma-bearing rats
Sigrid Hatse
,
Bart Degrève
,
De Clercq Erik
,
Michel Vandeputte
,
Mark Waer
,
Jan Balzarini
Article
1995
In vivo Antiretroviral Efficacy of Oral bis(POM)-PMEA, the bis(Pivaloyloxymethyl)prodrug of 9-(2-Phosphonylmethoxyethyl) adenine (PMEA)
Lieve Naesens
,
Johan Neyts
,
Jan Balzarini
,
N. Bischofberger
,
De Clercq Erik
Article
1989
Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.
Jan Balzarini
,
Lieve Naesens
,
Piet Herdewijn
,
Ivan Rosenberg
,
Antonı́n Holý
,
Rudi Pauwels
,
Masanori Baba
,
David G. Johns
,
De Clercq Erik
Article
1991
Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo
Lieve Naesens
,
Jan Balzarini
,
De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.